Key Takeaways: How Varenicline Works

Active Ingredient: Varenicline (as tartrate) – a selective nicotinic receptor partial agonist.
Primary Action: Binds to α4β2 receptors in the brain, partially stimulating them to reduce cravings while blocking nicotine's effects.
Clinical Result: Reduces withdrawal symptoms and the pleasure of smoking, doubling quit rates versus placebo.
Onset & Duration: Steady state reached within 4 days; half-life ~24 hours, allowing twice-daily dosing.
Metabolism: Minimal hepatic metabolism; 92% excreted unchanged in urine. Dose adjustment needed in severe kidney impairment.

Varenicline works by gently stimulating nicotine receptors in the brain to ease cravings and withdrawal, while simultaneously blocking the rewarding hit of nicotine if you slip. This dual action makes it one of the most effective smoking cessation aids available.

Important Safety Information

Stop varenicline and contact a doctor immediately if you experience: agitation, depressed mood, suicidal thoughts, or changes in behaviour; swelling of face, lips, tongue or throat (allergic reaction); severe skin rash or blistering; seizures; new or worse heart symptoms (chest pain, shortness of breath). These are rare but serious side effects.

Chemical Composition & Molecular Structure

Varenicline (as tartrate) is a synthetic derivative of cytisine, a plant alkaloid. Its molecular formula is C₁₃H₁₃N₃ (free base) and it is supplied as the tartrate salt for improved solubility.

Structural Details

Active moiety

7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine

A rigid, three‑ring structure that mimics the binding of nicotine to α4β2 receptors.

Salt form

Varenicline tartrate (1:1)

Each 0.5 mg or 1 mg tablet contains the equivalent of varenicline base, with tartaric acid enhancing dissolution.

Excipients (tablet core)

Microcrystalline cellulose, calcium hydrogen phosphate dihydrate, croscarmellose sodium, stearic acid

Film coating: hypromellose, titanium dioxide (E171), macrogol 400; 1 mg tablets also contain indigo carmine aluminium lake (E132).

Key Pharmaceutical Properties

Property	Value
Molecular weight (base)	211.26 g/mol
pKa	9.2 (basic nitrogen)
LogP (octanol/water)	1.2 (moderately lipophilic)
Protein binding	≤20%
Bioavailability	High (≥90%), unaffected by food

🗒️ Pharmaceutical insight: The rigid molecular structure provides high selectivity for α4β2 nicotinic receptors, with negligible affinity for other receptor types (e.g., muscarinic, GABA), minimising off-target effects.

Mechanism of Action: Nicotinic Receptor Partial Agonist

Varenicline exerts its effect by binding to α4β2 neuronal nicotinic acetylcholine receptors, where it acts as a partial agonist.

Partial stimulation: It activates the receptor to about 40–60% of the maximal response of nicotine, releasing moderate dopamine in the nucleus accumbens – enough to reduce cravings and withdrawal symptoms.
Receptor blockade: By occupying the receptor, it prevents nicotine from binding, thereby blocking the full dopaminergic surge that would otherwise reinforce smoking.
Result: Smoking becomes less satisfying, and the urge to smoke diminishes over time.

Feature	Varenicline	Nicotine (from cigarettes)
Receptor activation	Partial (40-60%)	Full (100%)
Dopamine release	Moderate, steady	High, rapid spikes
Craving reduction	Yes, through mild stimulation	Only during smoking

🗒️ Neuropharmacology note: The partial agonist profile avoids the complete withdrawal of dopaminergic tone seen with antagonists (like bupropion), leading to better tolerability.

Absorption & Distribution

After oral administration, varenicline is almost completely absorbed, with peak plasma concentrations reached within 3–4 hours. Steady state is achieved after 4 days of regular dosing.

Absorption

Absolute bioavailability ~90%. Food does not affect absorption, so tablets can be taken with or without meals.

Distribution

Volume of distribution averages 415 L, indicating extensive tissue binding. Plasma protein binding is low (≤20%), so drug interactions via protein displacement are unlikely.

Metabolic Effects & Elimination

Varenicline undergoes minimal hepatic metabolism (<10%). The majority (92%) is excreted unchanged in urine via glomerular filtration and active tubular secretion. The elimination half-life is approximately 24 hours, allowing twice-daily dosing.

⚠️ Renal impairment: In patients with severe kidney disease (eGFR <30 mL/min), dose reduction is required; avoid use in end-stage renal disease unless benefit outweighs risk.

Unlike nicotine, varenicline does not induce or inhibit cytochrome P450 enzymes, making drug interactions less common. However, cimetidine (a gastric acid reducer) can increase varenicline levels by reducing renal secretion.

Clinical Efficacy for Smoking Cessation

Varenicline more than doubles the chances of quitting successfully compared with placebo. In clinical trials, continuous abstinence rates at weeks 9–12 were approximately 44% for varenicline vs. 18% for placebo.

12‑week course: typical quit rate 44% (validated by carbon monoxide testing).
Additional 12 weeks (maintenance) reduces relapse in those who have quit.
Flexible quit approach: set a quit date between days 8–14, or gradually reduce smoking over 12 weeks and quit by week 12.

Varenicline is also effective in smokers with cardiovascular disease or COPD, though monitoring is advised due to potential cardiovascular events (rare).

Varenicline FAQs

How long does varenicline take to start working?

Varenicline begins to reduce cravings from the first dose, but steady-state levels are reached after 4 days. Most people set their quit date between days 8 and 14 for maximum benefit.

Can I drink alcohol while taking varenicline?

Some people report increased intoxicating effects of alcohol. It is advisable to limit alcohol intake until you know how varenicline affects you.

What are the most common side effects?

Nausea (very common, usually mild and transient), abnormal dreams, insomnia, headache, and nasopharyngitis. Taking with food can help reduce nausea.

Can I use varenicline if I have kidney problems?

Yes, but dose adjustment is needed for severe kidney impairment (eGFR <30 mL/min). Your doctor will prescribe a lower dose. Avoid use with cimetidine if you have kidney disease.

Is varenicline safe during pregnancy?

Varenicline is not recommended in pregnancy. If you are pregnant or planning to become pregnant, discuss nicotine replacement therapy or behavioural support with your doctor.

Ready to Quit Smoking with Varenicline?

If you're motivated to stop smoking, varenicline can significantly improve your chances. A UK‑registered doctor can assess your suitability and provide a prescription.